Newsletter – June 23rd 2022
Characterising the physical properties of spray dried powders The benefits of powder characterisation When developing products containing spray dried powders it is vital that the
Menu
Your CDMO Specialist
Supporting You From Feasibility To Clinic
Upperton Pharma Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.
We offer our clients an extensive range of services, from early feasibility to dosage form development and clinical trial manufacturing.
Pre-Formulation Studies
Upperton’s formulation development team will confidently guide you on the best route forward.
Formulation Development
Utilise our expertise and know-how to solve problems unique to your challenging molecule.
Clinical Manufaturing
FIH through to phase II clinical
manufacturing. No project is too small or too challenging.
Can we help you?
About Us
Upperton Pharma Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.
Pharma Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.
Solutions is an early phase Pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with more than twenty years of experience in the development of pharmaceutical dosage forms.
Latest news
23rd May 2022 – Upperton Pharma Solutions announces £15m investment in new facilities
Upperton Pharma Solutions announces £15m investment in new facilities Upperton Pharma Solutions (Upperton), a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a
21st April 2022 – Inflexion announces investment into Upperton
21st April 2022 – Inflexion announces investment into Upperton Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”),